CC
The Chemours Company11.69
-0.09-0.76%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.75BP/E (TTM)
-Basic EPS (TTM)
-2.13Dividend Yield
0.06%Recent Filings
8-K
Chemours launches executive severance policy
The Chemours Company adopted its Executive Severance Policy on October 28, 2025, targeting retention of senior management amid potential disruptions. It offers the CEO 2.0 times base salary, target incentive, and health subsidy upon qualifying termination, while other executives get 1.0 times—plus prorated incentives based on actual performance. Benefits hinge on a release of claims. This bolsters leadership stability, yet ties payouts to non-compete adherence.
8-K
Chemours has entered into a $1.05 billion Term Loan B-4 to refinance existing debt, extending maturity to 2032. Additionally, a €180 million receivables purchase program was established with BNP Paribas Factor for Chemours' European entities, enhancing liquidity.
8-K
Chemours appoints new board chair
The Chemours Company appointed Independent Director Mary Cranston as Board Chair and Alister Cowan as Lead Independent Director, effective September 2, 2025. This reshuffle follows Dawn Farrell's exit to helm Canada's new Major Projects Office. Leadership transitions like this sharpen governance focus. No further impacts disclosed.
8-K
Chemours Chair Farrell resigns
The Chemours Company announced on August 29, 2025, that Board Chair Dawn Farrell will resign effective September 2, 2025, to lead Canada's new Major Projects Office under the Building Canada Act. No successor has been named yet; an announcement is pending. This abrupt shift leaves leadership in flux. The move underscores her pull toward public service, but Chemours must act swiftly to stabilize governance.
8-K
Q2 sales up, but settlement hits
Chemours posted Q2 net sales of $1.6 billion, up 4% year-over-year, fueled by 65% growth in Opteon™ Refrigerants amid U.S. AIM Act transitions, though a $257 million New Jersey PFAS settlement charge flipped net income to a $381 million loss. Adjusted EBITDA climbed 22% to $253 million, with TSS margins expanding to 35% on volume surges, while TT grappled with $23 million in operational disruptions. Settlement payments, net present value $250 million over 25 years, are fully funded through 2030 via insurance and escrow. Q3 Adjusted EBITDA guidance: $175-195 million.
IPO
Website
Employees
Sector
Industry
AVNT
Avient Corporation
30.50+0.02
CBT
Cabot Corporation
68.00-0.70
CE
Celanese Corporation
40.95-1.54
DD
DuPont de Nemours, Inc.
40.45-0.16
EMN
Eastman Chemical Company
63.65-0.30
ESI
Element Solutions Inc.
25.53-0.53
HUN
Huntsman Corporation
9.90-0.51
KRO
Kronos Worldwide Inc
4.67-0.20
PPG
PPG Industries, Inc.
103.70-0.02
SHW
Sherwin-Williams Company (The)
327.87-0.58